Impacts of Latitude and Stampede: Urologist and Urologic Oncologist's Perspective

(Length of lecture ~ 36 minutes)

Alicia Morgans hosts a discussion with David Penson, Charles Ryan and Neal Shore regarding impacts of LATITUDE and STAMPEDE data from a urologist and urologic oncologists perspective, taking in to account the recently updated data from the CHAARTED trial.

Specifically, discussed was treating patients that have high-volume, aggressive metastatic prostate cancer that is hormone-senstivie with docetaxal, and the possiblity of giving patients abiraterone in addition to androgen deprivation therapy (ADT). Considerations noted during the conversation included the heterogenity of the patient, the stage of the disease, regional availability of the drugs, and cost as well as having an open discussion with the patient to outline the pros and cons of each treatment option based on the current disease state.

Additional Content on LATITUDE and STAMPEDE trials

5 for 5: Discussion on CHAARTED, LATITUDE and STAMPEDE Trials

ASCO 2017: Discussion of LATITUDE and STAMPEDE Trials

A Clinical Conversation with Alicia Morgans and Charles Ryan: Considerations of ASCO 2017 LATITUDE and STAMPEDE

Crashing into progress: New findings meet old habits 


Alicia Morgans

Charles Ryan 

Neal Shore

David Penson
Professor of Urologic Surgery and Medicine, Vanderbuilt University Medical Center
Nashville, TN

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.